nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—SRC—periosteum—osteoporosis	0.00667	0.0437	CbGeAlD
Bosutinib—CSF1R—periosteum—osteoporosis	0.00599	0.0392	CbGeAlD
Bosutinib—ABCB1—Ethinyl Estradiol—osteoporosis	0.00272	0.133	CbGbCtD
Bosutinib—CYP3A4—Estropipate—osteoporosis	0.00253	0.124	CbGbCtD
Bosutinib—CYP3A4—Calcitriol—osteoporosis	0.00253	0.124	CbGbCtD
Bosutinib—STK33—uterus—osteoporosis	0.0024	0.0157	CbGeAlD
Bosutinib—BMX—uterus—osteoporosis	0.00228	0.0149	CbGeAlD
Bosutinib—CLK3—uterus—osteoporosis	0.00228	0.0149	CbGeAlD
Bosutinib—EIF2AK1—uterus—osteoporosis	0.00221	0.0144	CbGeAlD
Bosutinib—SRMS—uterus—osteoporosis	0.00218	0.0143	CbGeAlD
Bosutinib—FES—uterus—osteoporosis	0.00214	0.014	CbGeAlD
Bosutinib—SYK—uterus—osteoporosis	0.0021	0.0137	CbGeAlD
Bosutinib—CDK2—uterus—osteoporosis	0.00208	0.0136	CbGeAlD
Bosutinib—PRKCQ—bone marrow—osteoporosis	0.00206	0.0135	CbGeAlD
Bosutinib—STK26—uterus—osteoporosis	0.00206	0.0135	CbGeAlD
Bosutinib—CYP3A4—Ergocalciferol—osteoporosis	0.00202	0.0991	CbGbCtD
Bosutinib—ABCB1—Conjugated Estrogens—osteoporosis	0.002	0.0978	CbGbCtD
Bosutinib—PKMYT1—bone marrow—osteoporosis	0.00198	0.013	CbGeAlD
Bosutinib—DMPK—uterus—osteoporosis	0.00197	0.0129	CbGeAlD
Bosutinib—WEE1—uterus—osteoporosis	0.00197	0.0129	CbGeAlD
Bosutinib—BMX—bone marrow—osteoporosis	0.00194	0.0127	CbGeAlD
Bosutinib—CLK3—bone marrow—osteoporosis	0.00194	0.0127	CbGeAlD
Bosutinib—STK25—uterus—osteoporosis	0.00188	0.0123	CbGeAlD
Bosutinib—EIF2AK1—bone marrow—osteoporosis	0.00187	0.0123	CbGeAlD
Bosutinib—SRMS—bone marrow—osteoporosis	0.00185	0.0121	CbGeAlD
Bosutinib—TXK—bone marrow—osteoporosis	0.00183	0.012	CbGeAlD
Bosutinib—PLK2—uterus—osteoporosis	0.00183	0.012	CbGeAlD
Bosutinib—SIK3—uterus—osteoporosis	0.00182	0.0119	CbGeAlD
Bosutinib—VRK2—bone marrow—osteoporosis	0.00181	0.0119	CbGeAlD
Bosutinib—FES—bone marrow—osteoporosis	0.00181	0.0119	CbGeAlD
Bosutinib—SYK—bone marrow—osteoporosis	0.00178	0.0117	CbGeAlD
Bosutinib—CDK2—bone marrow—osteoporosis	0.00176	0.0115	CbGeAlD
Bosutinib—ABCB1—Estradiol—osteoporosis	0.00175	0.0859	CbGbCtD
Bosutinib—STK26—bone marrow—osteoporosis	0.00175	0.0114	CbGeAlD
Bosutinib—STK24—uterus—osteoporosis	0.00171	0.0112	CbGeAlD
Bosutinib—CYP3A4—Raloxifene—osteoporosis	0.00169	0.0827	CbGbCtD
Bosutinib—CHEK2—bone marrow—osteoporosis	0.00169	0.011	CbGeAlD
Bosutinib—WEE1—bone marrow—osteoporosis	0.00167	0.011	CbGeAlD
Bosutinib—CYP3A4—Ethinyl Estradiol—osteoporosis	0.00163	0.0798	CbGbCtD
Bosutinib—STK25—bone marrow—osteoporosis	0.0016	0.0105	CbGeAlD
Bosutinib—TNK2—uterus—osteoporosis	0.00159	0.0104	CbGeAlD
Bosutinib—MAP4K2—uterus—osteoporosis	0.00157	0.0103	CbGeAlD
Bosutinib—STK3—uterus—osteoporosis	0.00155	0.0101	CbGeAlD
Bosutinib—BMPR2—uterus—osteoporosis	0.00148	0.00971	CbGeAlD
Bosutinib—EPHB3—uterus—osteoporosis	0.00147	0.00963	CbGeAlD
Bosutinib—STK24—bone marrow—osteoporosis	0.00145	0.0095	CbGeAlD
Bosutinib—STK25—Estriol—Estropipate—osteoporosis	0.00145	0.173	CbGdCrCtD
Bosutinib—MAP4K4—uterus—osteoporosis	0.00143	0.00934	CbGeAlD
Bosutinib—BCR—uterus—osteoporosis	0.00142	0.00928	CbGeAlD
Bosutinib—MAP4K1—bone marrow—osteoporosis	0.00137	0.00901	CbGeAlD
Bosutinib—CSK—uterus—osteoporosis	0.00137	0.00896	CbGeAlD
Bosutinib—BTK—bone marrow—osteoporosis	0.00137	0.00896	CbGeAlD
Bosutinib—CSNK1A1—uterus—osteoporosis	0.00136	0.00891	CbGeAlD
Bosutinib—HCK—uterus—osteoporosis	0.00135	0.00885	CbGeAlD
Bosutinib—CLK1—uterus—osteoporosis	0.00135	0.00885	CbGeAlD
Bosutinib—MAP4K2—bone marrow—osteoporosis	0.00133	0.00871	CbGeAlD
Bosutinib—CAMK2G—uterus—osteoporosis	0.00133	0.00869	CbGeAlD
Bosutinib—EGFR—uterus—osteoporosis	0.00131	0.00858	CbGeAlD
Bosutinib—CYP3A4—Cholecalciferol—osteoporosis	0.0013	0.0638	CbGbCtD
Bosutinib—CSNK1E—uterus—osteoporosis	0.00126	0.00825	CbGeAlD
Bosutinib—SIK1—uterus—osteoporosis	0.00124	0.00812	CbGeAlD
Bosutinib—MERTK—bone marrow—osteoporosis	0.00123	0.00808	CbGeAlD
Bosutinib—EPHA4—uterus—osteoporosis	0.00123	0.00804	CbGeAlD
Bosutinib—ERBB3—uterus—osteoporosis	0.00122	0.00796	CbGeAlD
Bosutinib—ULK3—uterus—osteoporosis	0.00121	0.00794	CbGeAlD
Bosutinib—MAP2K2—uterus—osteoporosis	0.00121	0.00794	CbGeAlD
Bosutinib—MAP4K4—bone marrow—osteoporosis	0.00121	0.00793	CbGeAlD
Bosutinib—MAP3K2—uterus—osteoporosis	0.0012	0.00789	CbGeAlD
Bosutinib—NUAK2—bone marrow—osteoporosis	0.0012	0.00787	CbGeAlD
Bosutinib—BCR—bone marrow—osteoporosis	0.0012	0.00787	CbGeAlD
Bosutinib—CYP3A4—Conjugated Estrogens—osteoporosis	0.0012	0.0586	CbGbCtD
Bosutinib—MAP3K7—uterus—osteoporosis	0.00119	0.00781	CbGeAlD
Bosutinib—PTK2—uterus—osteoporosis	0.00118	0.00772	CbGeAlD
Bosutinib—MAP2K1—bone marrow—osteoporosis	0.00117	0.00766	CbGeAlD
Bosutinib—CSK—bone marrow—osteoporosis	0.00116	0.00761	CbGeAlD
Bosutinib—CSNK1A1—bone marrow—osteoporosis	0.00115	0.00756	CbGeAlD
Bosutinib—HCK—bone marrow—osteoporosis	0.00115	0.00751	CbGeAlD
Bosutinib—CLK1—bone marrow—osteoporosis	0.00115	0.00751	CbGeAlD
Bosutinib—LCK—uterus—osteoporosis	0.00113	0.00739	CbGeAlD
Bosutinib—CAMK2G—bone marrow—osteoporosis	0.00113	0.00737	CbGeAlD
Bosutinib—BMP2K—bone marrow—osteoporosis	0.00113	0.00737	CbGeAlD
Bosutinib—AXL—uterus—osteoporosis	0.00112	0.00736	CbGeAlD
Bosutinib—LRRK2—bone marrow—osteoporosis	0.00112	0.00731	CbGeAlD
Bosutinib—STK25—Estriol—Conjugated Estrogens—osteoporosis	0.0011	0.131	CbGdCrCtD
Bosutinib—PTK2B—bone marrow—osteoporosis	0.00109	0.00712	CbGeAlD
Bosutinib—SLK—uterus—osteoporosis	0.00108	0.00708	CbGeAlD
Bosutinib—EPHB4—uterus—osteoporosis	0.00107	0.00703	CbGeAlD
Bosutinib—SIK1—bone marrow—osteoporosis	0.00105	0.00689	CbGeAlD
Bosutinib—IRAK4—bone marrow—osteoporosis	0.00105	0.00689	CbGeAlD
Bosutinib—CYP3A4—Estradiol—osteoporosis	0.00105	0.0515	CbGbCtD
Bosutinib—FYN—uterus—osteoporosis	0.00105	0.00688	CbGeAlD
Bosutinib—MAP2K2—bone marrow—osteoporosis	0.00103	0.00674	CbGeAlD
Bosutinib—ULK3—bone marrow—osteoporosis	0.00103	0.00674	CbGeAlD
Bosutinib—MAP4K5—uterus—osteoporosis	0.00103	0.00673	CbGeAlD
Bosutinib—MAP3K2—bone marrow—osteoporosis	0.00102	0.00669	CbGeAlD
Bosutinib—MAP3K7—bone marrow—osteoporosis	0.00101	0.00663	CbGeAlD
Bosutinib—TBK1—bone marrow—osteoporosis	0.001	0.00656	CbGeAlD
Bosutinib—IRAK1—bone marrow—osteoporosis	0.000981	0.00643	CbGeAlD
Bosutinib—RPS6KB1—bone marrow—osteoporosis	0.000963	0.00631	CbGeAlD
Bosutinib—PKMYT1—Fulvestrant—Estradiol—osteoporosis	0.000957	0.114	CbGdCrCtD
Bosutinib—FGR—bone marrow—osteoporosis	0.000957	0.00627	CbGeAlD
Bosutinib—LCK—bone marrow—osteoporosis	0.000957	0.00627	CbGeAlD
Bosutinib—YES1—uterus—osteoporosis	0.000949	0.00621	CbGeAlD
Bosutinib—STK25—Estriol—Estradiol—osteoporosis	0.000945	0.113	CbGdCrCtD
Bosutinib—STK10—uterus—osteoporosis	0.00094	0.00616	CbGeAlD
Bosutinib—TAOK3—uterus—osteoporosis	0.000936	0.00613	CbGeAlD
Bosutinib—STK25—Estriol—Ethinyl Estradiol—osteoporosis	0.000922	0.11	CbGdCrCtD
Bosutinib—SLK—bone marrow—osteoporosis	0.000917	0.00601	CbGeAlD
Bosutinib—EPHB4—bone marrow—osteoporosis	0.000911	0.00597	CbGeAlD
Bosutinib—PLK2—Levonorgestrel—Ethinyl Estradiol—osteoporosis	0.000908	0.108	CbGdCrCtD
Bosutinib—FYN—bone marrow—osteoporosis	0.000892	0.00584	CbGeAlD
Bosutinib—MAP4K5—bone marrow—osteoporosis	0.000872	0.00571	CbGeAlD
Bosutinib—MAP3K3—bone marrow—osteoporosis	0.000872	0.00571	CbGeAlD
Bosutinib—CSF1R—uterus—osteoporosis	0.000819	0.00537	CbGeAlD
Bosutinib—YES1—bone marrow—osteoporosis	0.000805	0.00527	CbGeAlD
Bosutinib—STK10—bone marrow—osteoporosis	0.000798	0.00523	CbGeAlD
Bosutinib—TAOK3—bone marrow—osteoporosis	0.000795	0.00521	CbGeAlD
Bosutinib—PDGFRB—uterus—osteoporosis	0.000727	0.00476	CbGeAlD
Bosutinib—CSF1R—bone marrow—osteoporosis	0.000695	0.00455	CbGeAlD
Bosutinib—ABL1—uterus—osteoporosis	0.000648	0.00424	CbGeAlD
Bosutinib—PDGFRB—bone marrow—osteoporosis	0.000617	0.00404	CbGeAlD
Bosutinib—ABL1—bone marrow—osteoporosis	0.00055	0.0036	CbGeAlD
Bosutinib—CHEK2—Fulvestrant—Estradiol—osteoporosis	0.000467	0.0557	CbGdCrCtD
Bosutinib—Gastrointestinal pain—Alendronate—osteoporosis	0.000431	0.00125	CcSEcCtD
Bosutinib—Infection—Ethinyl Estradiol—osteoporosis	0.000431	0.00125	CcSEcCtD
Bosutinib—Cough—Pamidronate—osteoporosis	0.00043	0.00125	CcSEcCtD
Bosutinib—Pain—Calcitriol—osteoporosis	0.00043	0.00125	CcSEcCtD
Bosutinib—Nervous system disorder—Ethinyl Estradiol—osteoporosis	0.000426	0.00123	CcSEcCtD
Bosutinib—Urticaria—Estropipate—osteoporosis	0.000425	0.00123	CcSEcCtD
Bosutinib—Dysgeusia—Conjugated Estrogens—osteoporosis	0.000425	0.00123	CcSEcCtD
Bosutinib—Gastrointestinal pain—Raloxifene—osteoporosis	0.000424	0.00123	CcSEcCtD
Bosutinib—Diarrhoea—Etidronic acid—osteoporosis	0.000424	0.00123	CcSEcCtD
Bosutinib—Body temperature increased—Estropipate—osteoporosis	0.000423	0.00123	CcSEcCtD
Bosutinib—Abdominal pain—Estropipate—osteoporosis	0.000423	0.00123	CcSEcCtD
Bosutinib—Feeling abnormal—Ibandronate—osteoporosis	0.000423	0.00123	CcSEcCtD
Bosutinib—Skin disorder—Ethinyl Estradiol—osteoporosis	0.000422	0.00122	CcSEcCtD
Bosutinib—Infection—Risedronate—osteoporosis	0.00042	0.00122	CcSEcCtD
Bosutinib—Hepatobiliary disease—Estradiol—osteoporosis	0.00042	0.00122	CcSEcCtD
Bosutinib—Gastrointestinal pain—Ibandronate—osteoporosis	0.00042	0.00122	CcSEcCtD
Bosutinib—Arthralgia—Pamidronate—osteoporosis	0.00042	0.00122	CcSEcCtD
Bosutinib—Myalgia—Pamidronate—osteoporosis	0.00042	0.00122	CcSEcCtD
Bosutinib—Back pain—Conjugated Estrogens—osteoporosis	0.000419	0.00122	CcSEcCtD
Bosutinib—Urticaria—Alendronate—osteoporosis	0.000419	0.00121	CcSEcCtD
Bosutinib—PKMYT1—Danazol—Ethinyl Estradiol—osteoporosis	0.000418	0.0498	CbGdCrCtD
Bosutinib—Ill-defined disorder—Zoledronate—osteoporosis	0.000418	0.00121	CcSEcCtD
Bosutinib—Abdominal pain—Alendronate—osteoporosis	0.000417	0.00121	CcSEcCtD
Bosutinib—Body temperature increased—Alendronate—osteoporosis	0.000417	0.00121	CcSEcCtD
Bosutinib—Anaemia—Zoledronate—osteoporosis	0.000416	0.00121	CcSEcCtD
Bosutinib—Nervous system disorder—Risedronate—osteoporosis	0.000415	0.0012	CcSEcCtD
Bosutinib—Discomfort—Pamidronate—osteoporosis	0.000415	0.0012	CcSEcCtD
Bosutinib—Skin disorder—Risedronate—osteoporosis	0.000411	0.00119	CcSEcCtD
Bosutinib—Gastrointestinal pain—Calcitriol—osteoporosis	0.000411	0.00119	CcSEcCtD
Bosutinib—Abdominal pain—Raloxifene—osteoporosis	0.00041	0.00119	CcSEcCtD
Bosutinib—Body temperature increased—Raloxifene—osteoporosis	0.00041	0.00119	CcSEcCtD
Bosutinib—Urticaria—Ibandronate—osteoporosis	0.000408	0.00118	CcSEcCtD
Bosutinib—Malaise—Zoledronate—osteoporosis	0.000406	0.00118	CcSEcCtD
Bosutinib—Body temperature increased—Ibandronate—osteoporosis	0.000406	0.00118	CcSEcCtD
Bosutinib—Abdominal pain—Ibandronate—osteoporosis	0.000406	0.00118	CcSEcCtD
Bosutinib—Leukopenia—Zoledronate—osteoporosis	0.000403	0.00117	CcSEcCtD
Bosutinib—Oedema—Pamidronate—osteoporosis	0.000402	0.00117	CcSEcCtD
Bosutinib—Anaphylactic shock—Pamidronate—osteoporosis	0.000402	0.00117	CcSEcCtD
Bosutinib—Infection—Pamidronate—osteoporosis	0.0004	0.00116	CcSEcCtD
Bosutinib—Urticaria—Calcitriol—osteoporosis	0.000399	0.00116	CcSEcCtD
Bosutinib—Hepatitis—Estradiol—osteoporosis	0.000399	0.00116	CcSEcCtD
Bosutinib—CSNK1E—Danazol—Ethinyl Estradiol—osteoporosis	0.000399	0.0475	CbGdCrCtD
Bosutinib—Body temperature increased—Calcitriol—osteoporosis	0.000397	0.00115	CcSEcCtD
Bosutinib—Abdominal pain—Calcitriol—osteoporosis	0.000397	0.00115	CcSEcCtD
Bosutinib—Nervous system disorder—Pamidronate—osteoporosis	0.000395	0.00114	CcSEcCtD
Bosutinib—Thrombocytopenia—Pamidronate—osteoporosis	0.000394	0.00114	CcSEcCtD
Bosutinib—Urinary tract disorder—Estradiol—osteoporosis	0.000394	0.00114	CcSEcCtD
Bosutinib—Vomiting—Etidronic acid—osteoporosis	0.000394	0.00114	CcSEcCtD
Bosutinib—Cough—Zoledronate—osteoporosis	0.000393	0.00114	CcSEcCtD
Bosutinib—Oedema peripheral—Estradiol—osteoporosis	0.000393	0.00114	CcSEcCtD
Bosutinib—Connective tissue disorder—Estradiol—osteoporosis	0.000392	0.00114	CcSEcCtD
Bosutinib—Urethral disorder—Estradiol—osteoporosis	0.000391	0.00113	CcSEcCtD
Bosutinib—Rash—Etidronic acid—osteoporosis	0.00039	0.00113	CcSEcCtD
Bosutinib—Dermatitis—Etidronic acid—osteoporosis	0.00039	0.00113	CcSEcCtD
Bosutinib—Headache—Etidronic acid—osteoporosis	0.000388	0.00112	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Risedronate—osteoporosis	0.000386	0.00112	CcSEcCtD
Bosutinib—Asthenia—Estropipate—osteoporosis	0.000384	0.00111	CcSEcCtD
Bosutinib—Myalgia—Zoledronate—osteoporosis	0.000383	0.00111	CcSEcCtD
Bosutinib—Arthralgia—Zoledronate—osteoporosis	0.000383	0.00111	CcSEcCtD
Bosutinib—Chest pain—Zoledronate—osteoporosis	0.000383	0.00111	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000381	0.0011	CcSEcCtD
Bosutinib—Pruritus—Estropipate—osteoporosis	0.000379	0.0011	CcSEcCtD
Bosutinib—Discomfort—Zoledronate—osteoporosis	0.000379	0.0011	CcSEcCtD
Bosutinib—Asthenia—Alendronate—osteoporosis	0.000378	0.0011	CcSEcCtD
Bosutinib—Cough—Conjugated Estrogens—osteoporosis	0.000378	0.0011	CcSEcCtD
Bosutinib—Dyspnoea—Risedronate—osteoporosis	0.000377	0.00109	CcSEcCtD
Bosutinib—Erythema multiforme—Estradiol—osteoporosis	0.000377	0.00109	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000375	0.00109	CcSEcCtD
Bosutinib—Fatigue—Ethinyl Estradiol—osteoporosis	0.000374	0.00108	CcSEcCtD
Bosutinib—Pruritus—Alendronate—osteoporosis	0.000373	0.00108	CcSEcCtD
Bosutinib—Tinnitus—Estradiol—osteoporosis	0.000372	0.00108	CcSEcCtD
Bosutinib—Cardiac disorder—Estradiol—osteoporosis	0.00037	0.00107	CcSEcCtD
Bosutinib—Chest pain—Conjugated Estrogens—osteoporosis	0.000369	0.00107	CcSEcCtD
Bosutinib—Arthralgia—Conjugated Estrogens—osteoporosis	0.000369	0.00107	CcSEcCtD
Bosutinib—Myalgia—Conjugated Estrogens—osteoporosis	0.000369	0.00107	CcSEcCtD
Bosutinib—Asthenia—Ibandronate—osteoporosis	0.000368	0.00107	CcSEcCtD
Bosutinib—Nausea—Etidronic acid—osteoporosis	0.000368	0.00107	CcSEcCtD
Bosutinib—Oedema—Zoledronate—osteoporosis	0.000367	0.00107	CcSEcCtD
Bosutinib—Anaphylactic shock—Zoledronate—osteoporosis	0.000367	0.00107	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000367	0.00106	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000367	0.00106	CcSEcCtD
Bosutinib—Diarrhoea—Estropipate—osteoporosis	0.000366	0.00106	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Risedronate—osteoporosis	0.000365	0.00106	CcSEcCtD
Bosutinib—Infection—Zoledronate—osteoporosis	0.000365	0.00106	CcSEcCtD
Bosutinib—Fatigue—Risedronate—osteoporosis	0.000365	0.00106	CcSEcCtD
Bosutinib—Pruritus—Ibandronate—osteoporosis	0.000363	0.00105	CcSEcCtD
Bosutinib—Pain—Risedronate—osteoporosis	0.000362	0.00105	CcSEcCtD
Bosutinib—Diarrhoea—Alendronate—osteoporosis	0.000361	0.00105	CcSEcCtD
Bosutinib—Asthenia—Calcitriol—osteoporosis	0.000361	0.00105	CcSEcCtD
Bosutinib—Nervous system disorder—Zoledronate—osteoporosis	0.00036	0.00104	CcSEcCtD
Bosutinib—Immune system disorder—Estradiol—osteoporosis	0.00036	0.00104	CcSEcCtD
Bosutinib—Thrombocytopenia—Zoledronate—osteoporosis	0.00036	0.00104	CcSEcCtD
Bosutinib—Mediastinal disorder—Estradiol—osteoporosis	0.000359	0.00104	CcSEcCtD
Bosutinib—Dyspnoea—Pamidronate—osteoporosis	0.000359	0.00104	CcSEcCtD
Bosutinib—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000358	0.00104	CcSEcCtD
Bosutinib—Skin disorder—Zoledronate—osteoporosis	0.000357	0.00103	CcSEcCtD
Bosutinib—Pruritus—Calcitriol—osteoporosis	0.000356	0.00103	CcSEcCtD
Bosutinib—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000355	0.00103	CcSEcCtD
Bosutinib—Diarrhoea—Raloxifene—osteoporosis	0.000355	0.00103	CcSEcCtD
Bosutinib—Dizziness—Estropipate—osteoporosis	0.000354	0.00103	CcSEcCtD
Bosutinib—Oedema—Conjugated Estrogens—osteoporosis	0.000354	0.00103	CcSEcCtD
Bosutinib—Anaphylactic shock—Conjugated Estrogens—osteoporosis	0.000354	0.00103	CcSEcCtD
Bosutinib—Infection—Conjugated Estrogens—osteoporosis	0.000352	0.00102	CcSEcCtD
Bosutinib—Diarrhoea—Ibandronate—osteoporosis	0.000351	0.00102	CcSEcCtD
Bosutinib—Decreased appetite—Pamidronate—osteoporosis	0.00035	0.00101	CcSEcCtD
Bosutinib—Dizziness—Alendronate—osteoporosis	0.000349	0.00101	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000347	0.00101	CcSEcCtD
Bosutinib—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000347	0.00101	CcSEcCtD
Bosutinib—Malnutrition—Estradiol—osteoporosis	0.000347	0.00101	CcSEcCtD
Bosutinib—Fatigue—Pamidronate—osteoporosis	0.000347	0.00101	CcSEcCtD
Bosutinib—Gastrointestinal pain—Risedronate—osteoporosis	0.000346	0.001	CcSEcCtD
Bosutinib—Urticaria—Ethinyl Estradiol—osteoporosis	0.000345	0.001	CcSEcCtD
Bosutinib—Pain—Pamidronate—osteoporosis	0.000344	0.000997	CcSEcCtD
Bosutinib—Diarrhoea—Calcitriol—osteoporosis	0.000344	0.000997	CcSEcCtD
Bosutinib—Skin disorder—Conjugated Estrogens—osteoporosis	0.000344	0.000996	CcSEcCtD
Bosutinib—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000343	0.000995	CcSEcCtD
Bosutinib—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000343	0.000995	CcSEcCtD
Bosutinib—Dizziness—Raloxifene—osteoporosis	0.000343	0.000995	CcSEcCtD
Bosutinib—Vomiting—Estropipate—osteoporosis	0.00034	0.000987	CcSEcCtD
Bosutinib—Dysgeusia—Estradiol—osteoporosis	0.00034	0.000985	CcSEcCtD
Bosutinib—Dizziness—Ibandronate—osteoporosis	0.00034	0.000985	CcSEcCtD
Bosutinib—Rash—Estropipate—osteoporosis	0.000338	0.000979	CcSEcCtD
Bosutinib—Dermatitis—Estropipate—osteoporosis	0.000337	0.000978	CcSEcCtD
Bosutinib—Urticaria—Risedronate—osteoporosis	0.000336	0.000975	CcSEcCtD
Bosutinib—Back pain—Estradiol—osteoporosis	0.000336	0.000973	CcSEcCtD
Bosutinib—Headache—Estropipate—osteoporosis	0.000335	0.000973	CcSEcCtD
Bosutinib—Vomiting—Alendronate—osteoporosis	0.000335	0.000972	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000335	0.000971	CcSEcCtD
Bosutinib—Abdominal pain—Risedronate—osteoporosis	0.000335	0.00097	CcSEcCtD
Bosutinib—Body temperature increased—Risedronate—osteoporosis	0.000335	0.00097	CcSEcCtD
Bosutinib—Rash—Alendronate—osteoporosis	0.000333	0.000964	CcSEcCtD
Bosutinib—Dermatitis—Alendronate—osteoporosis	0.000332	0.000963	CcSEcCtD
Bosutinib—Feeling abnormal—Pamidronate—osteoporosis	0.000332	0.000961	CcSEcCtD
Bosutinib—Headache—Alendronate—osteoporosis	0.00033	0.000958	CcSEcCtD
Bosutinib—Vomiting—Raloxifene—osteoporosis	0.00033	0.000956	CcSEcCtD
Bosutinib—Gastrointestinal pain—Pamidronate—osteoporosis	0.000329	0.000954	CcSEcCtD
Bosutinib—Dyspnoea—Zoledronate—osteoporosis	0.000328	0.00095	CcSEcCtD
Bosutinib—Rash—Raloxifene—osteoporosis	0.000327	0.000948	CcSEcCtD
Bosutinib—Dermatitis—Raloxifene—osteoporosis	0.000327	0.000947	CcSEcCtD
Bosutinib—Vomiting—Ibandronate—osteoporosis	0.000327	0.000947	CcSEcCtD
Bosutinib—Headache—Raloxifene—osteoporosis	0.000325	0.000942	CcSEcCtD
Bosutinib—Rash—Ibandronate—osteoporosis	0.000324	0.000939	CcSEcCtD
Bosutinib—Dermatitis—Ibandronate—osteoporosis	0.000323	0.000938	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000322	0.000935	CcSEcCtD
Bosutinib—Ill-defined disorder—Estradiol—osteoporosis	0.000322	0.000933	CcSEcCtD
Bosutinib—Headache—Ibandronate—osteoporosis	0.000322	0.000933	CcSEcCtD
Bosutinib—Vomiting—Calcitriol—osteoporosis	0.00032	0.000927	CcSEcCtD
Bosutinib—Decreased appetite—Zoledronate—osteoporosis	0.000319	0.000926	CcSEcCtD
Bosutinib—Nausea—Estropipate—osteoporosis	0.000318	0.000922	CcSEcCtD
Bosutinib—Body temperature increased—Pamidronate—osteoporosis	0.000318	0.000922	CcSEcCtD
Bosutinib—Abdominal pain—Pamidronate—osteoporosis	0.000318	0.000922	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000317	0.00092	CcSEcCtD
Bosutinib—Rash—Calcitriol—osteoporosis	0.000317	0.000919	CcSEcCtD
Bosutinib—Fatigue—Zoledronate—osteoporosis	0.000317	0.000919	CcSEcCtD
Bosutinib—Dermatitis—Calcitriol—osteoporosis	0.000317	0.000918	CcSEcCtD
Bosutinib—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000315	0.000915	CcSEcCtD
Bosutinib—Headache—Calcitriol—osteoporosis	0.000315	0.000913	CcSEcCtD
Bosutinib—Pain—Zoledronate—osteoporosis	0.000314	0.000911	CcSEcCtD
Bosutinib—Nausea—Alendronate—osteoporosis	0.000313	0.000908	CcSEcCtD
Bosutinib—Malaise—Estradiol—osteoporosis	0.000313	0.000907	CcSEcCtD
Bosutinib—Asthenia—Ethinyl Estradiol—osteoporosis	0.000311	0.000903	CcSEcCtD
Bosutinib—Nausea—Raloxifene—osteoporosis	0.000308	0.000893	CcSEcCtD
Bosutinib—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000308	0.000892	CcSEcCtD
Bosutinib—Pruritus—Ethinyl Estradiol—osteoporosis	0.000307	0.00089	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000305	0.000886	CcSEcCtD
Bosutinib—Fatigue—Conjugated Estrogens—osteoporosis	0.000305	0.000884	CcSEcCtD
Bosutinib—Nausea—Ibandronate—osteoporosis	0.000305	0.000884	CcSEcCtD
Bosutinib—Asthenia—Risedronate—osteoporosis	0.000304	0.00088	CcSEcCtD
Bosutinib—Feeling abnormal—Zoledronate—osteoporosis	0.000303	0.000878	CcSEcCtD
Bosutinib—Cough—Estradiol—osteoporosis	0.000303	0.000878	CcSEcCtD
Bosutinib—Pain—Conjugated Estrogens—osteoporosis	0.000303	0.000877	CcSEcCtD
Bosutinib—Gastrointestinal pain—Zoledronate—osteoporosis	0.000301	0.000871	CcSEcCtD
Bosutinib—Pruritus—Risedronate—osteoporosis	0.000299	0.000868	CcSEcCtD
Bosutinib—Nausea—Calcitriol—osteoporosis	0.000299	0.000866	CcSEcCtD
Bosutinib—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000297	0.000861	CcSEcCtD
Bosutinib—Arthralgia—Estradiol—osteoporosis	0.000295	0.000856	CcSEcCtD
Bosutinib—Chest pain—Estradiol—osteoporosis	0.000295	0.000856	CcSEcCtD
Bosutinib—Myalgia—Estradiol—osteoporosis	0.000295	0.000856	CcSEcCtD
Bosutinib—ABL1—Levorphanol—Estradiol—osteoporosis	0.000295	0.0351	CbGdCrCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000293	0.000851	CcSEcCtD
Bosutinib—Urticaria—Zoledronate—osteoporosis	0.000292	0.000846	CcSEcCtD
Bosutinib—Discomfort—Estradiol—osteoporosis	0.000292	0.000846	CcSEcCtD
Bosutinib—Body temperature increased—Zoledronate—osteoporosis	0.000291	0.000842	CcSEcCtD
Bosutinib—Abdominal pain—Zoledronate—osteoporosis	0.000291	0.000842	CcSEcCtD
Bosutinib—Diarrhoea—Risedronate—osteoporosis	0.00029	0.00084	CcSEcCtD
Bosutinib—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000289	0.000839	CcSEcCtD
Bosutinib—Asthenia—Pamidronate—osteoporosis	0.000289	0.000837	CcSEcCtD
Bosutinib—Dizziness—Ethinyl Estradiol—osteoporosis	0.000287	0.000832	CcSEcCtD
Bosutinib—Pruritus—Pamidronate—osteoporosis	0.000285	0.000825	CcSEcCtD
Bosutinib—Oedema—Estradiol—osteoporosis	0.000283	0.000821	CcSEcCtD
Bosutinib—Anaphylactic shock—Estradiol—osteoporosis	0.000283	0.000821	CcSEcCtD
Bosutinib—Infection—Estradiol—osteoporosis	0.000281	0.000816	CcSEcCtD
Bosutinib—Urticaria—Conjugated Estrogens—osteoporosis	0.000281	0.000815	CcSEcCtD
Bosutinib—Dizziness—Risedronate—osteoporosis	0.00028	0.000811	CcSEcCtD
Bosutinib—Body temperature increased—Conjugated Estrogens—osteoporosis	0.00028	0.000811	CcSEcCtD
Bosutinib—Abdominal pain—Conjugated Estrogens—osteoporosis	0.00028	0.000811	CcSEcCtD
Bosutinib—Nervous system disorder—Estradiol—osteoporosis	0.000278	0.000805	CcSEcCtD
Bosutinib—Vomiting—Ethinyl Estradiol—osteoporosis	0.000276	0.0008	CcSEcCtD
Bosutinib—Diarrhoea—Pamidronate—osteoporosis	0.000275	0.000798	CcSEcCtD
Bosutinib—Skin disorder—Estradiol—osteoporosis	0.000275	0.000798	CcSEcCtD
Bosutinib—Rash—Ethinyl Estradiol—osteoporosis	0.000274	0.000793	CcSEcCtD
Bosutinib—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000273	0.000793	CcSEcCtD
Bosutinib—Headache—Ethinyl Estradiol—osteoporosis	0.000272	0.000788	CcSEcCtD
Bosutinib—Vomiting—Risedronate—osteoporosis	0.000269	0.00078	CcSEcCtD
Bosutinib—Rash—Risedronate—osteoporosis	0.000267	0.000774	CcSEcCtD
Bosutinib—Dermatitis—Risedronate—osteoporosis	0.000267	0.000773	CcSEcCtD
Bosutinib—Dizziness—Pamidronate—osteoporosis	0.000266	0.000771	CcSEcCtD
Bosutinib—Headache—Risedronate—osteoporosis	0.000265	0.000769	CcSEcCtD
Bosutinib—Asthenia—Zoledronate—osteoporosis	0.000264	0.000764	CcSEcCtD
Bosutinib—Pruritus—Zoledronate—osteoporosis	0.00026	0.000754	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000258	0.000748	CcSEcCtD
Bosutinib—Nausea—Ethinyl Estradiol—osteoporosis	0.000258	0.000748	CcSEcCtD
Bosutinib—Vomiting—Pamidronate—osteoporosis	0.000256	0.000742	CcSEcCtD
Bosutinib—Asthenia—Conjugated Estrogens—osteoporosis	0.000254	0.000736	CcSEcCtD
Bosutinib—Rash—Pamidronate—osteoporosis	0.000254	0.000735	CcSEcCtD
Bosutinib—Dermatitis—Pamidronate—osteoporosis	0.000253	0.000735	CcSEcCtD
Bosutinib—Dyspnoea—Estradiol—osteoporosis	0.000252	0.000732	CcSEcCtD
Bosutinib—Headache—Pamidronate—osteoporosis	0.000252	0.000731	CcSEcCtD
Bosutinib—Diarrhoea—Zoledronate—osteoporosis	0.000251	0.000729	CcSEcCtD
Bosutinib—Nausea—Risedronate—osteoporosis	0.000251	0.000729	CcSEcCtD
Bosutinib—Pruritus—Conjugated Estrogens—osteoporosis	0.00025	0.000726	CcSEcCtD
Bosutinib—Decreased appetite—Estradiol—osteoporosis	0.000246	0.000714	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Estradiol—osteoporosis	0.000244	0.000709	CcSEcCtD
Bosutinib—Fatigue—Estradiol—osteoporosis	0.000244	0.000708	CcSEcCtD
Bosutinib—Dizziness—Zoledronate—osteoporosis	0.000243	0.000705	CcSEcCtD
Bosutinib—Pain—Estradiol—osteoporosis	0.000242	0.000702	CcSEcCtD
Bosutinib—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000242	0.000702	CcSEcCtD
Bosutinib—Nausea—Pamidronate—osteoporosis	0.000239	0.000693	CcSEcCtD
Bosutinib—Dizziness—Conjugated Estrogens—osteoporosis	0.000234	0.000678	CcSEcCtD
Bosutinib—Vomiting—Zoledronate—osteoporosis	0.000234	0.000677	CcSEcCtD
Bosutinib—Feeling abnormal—Estradiol—osteoporosis	0.000233	0.000677	CcSEcCtD
Bosutinib—Rash—Zoledronate—osteoporosis	0.000232	0.000672	CcSEcCtD
Bosutinib—Gastrointestinal pain—Estradiol—osteoporosis	0.000232	0.000671	CcSEcCtD
Bosutinib—Dermatitis—Zoledronate—osteoporosis	0.000231	0.000671	CcSEcCtD
Bosutinib—Headache—Zoledronate—osteoporosis	0.00023	0.000667	CcSEcCtD
Bosutinib—Vomiting—Conjugated Estrogens—osteoporosis	0.000225	0.000652	CcSEcCtD
Bosutinib—Urticaria—Estradiol—osteoporosis	0.000225	0.000652	CcSEcCtD
Bosutinib—Body temperature increased—Estradiol—osteoporosis	0.000224	0.000649	CcSEcCtD
Bosutinib—Abdominal pain—Estradiol—osteoporosis	0.000224	0.000649	CcSEcCtD
Bosutinib—Rash—Conjugated Estrogens—osteoporosis	0.000223	0.000647	CcSEcCtD
Bosutinib—Dermatitis—Conjugated Estrogens—osteoporosis	0.000223	0.000646	CcSEcCtD
Bosutinib—Headache—Conjugated Estrogens—osteoporosis	0.000222	0.000643	CcSEcCtD
Bosutinib—Nausea—Zoledronate—osteoporosis	0.000218	0.000633	CcSEcCtD
Bosutinib—Nausea—Conjugated Estrogens—osteoporosis	0.00021	0.000609	CcSEcCtD
Bosutinib—CHEK2—Danazol—Ethinyl Estradiol—osteoporosis	0.000204	0.0243	CbGdCrCtD
Bosutinib—Asthenia—Estradiol—osteoporosis	0.000203	0.000589	CcSEcCtD
Bosutinib—ABCB1—uterus—osteoporosis	0.000201	0.00132	CbGeAlD
Bosutinib—Pruritus—Estradiol—osteoporosis	0.0002	0.000581	CcSEcCtD
Bosutinib—Diarrhoea—Estradiol—osteoporosis	0.000194	0.000562	CcSEcCtD
Bosutinib—Dizziness—Estradiol—osteoporosis	0.000187	0.000543	CcSEcCtD
Bosutinib—CHEK2—Norethindrone—Ethinyl Estradiol—osteoporosis	0.000184	0.0219	CbGdCrCtD
Bosutinib—Vomiting—Estradiol—osteoporosis	0.00018	0.000522	CcSEcCtD
Bosutinib—Rash—Estradiol—osteoporosis	0.000179	0.000518	CcSEcCtD
Bosutinib—Dermatitis—Estradiol—osteoporosis	0.000178	0.000517	CcSEcCtD
Bosutinib—Headache—Estradiol—osteoporosis	0.000177	0.000514	CcSEcCtD
Bosutinib—ABCB1—bone marrow—osteoporosis	0.000171	0.00112	CbGeAlD
Bosutinib—Nausea—Estradiol—osteoporosis	0.000168	0.000488	CcSEcCtD
Bosutinib—CHEK2—Levonorgestrel—Ethinyl Estradiol—osteoporosis	0.000146	0.0174	CbGdCrCtD
Bosutinib—ABL1—Developmental Biology—IL6—osteoporosis	4.01e-06	8.46e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—MTHFR—osteoporosis	3.99e-06	8.43e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—SPP1—osteoporosis	3.99e-06	8.42e-06	CbGpPWpGaD
Bosutinib—FES—Signaling Pathways—IL6—osteoporosis	3.98e-06	8.41e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—IGF1—osteoporosis	3.97e-06	8.39e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—SPP1—osteoporosis	3.97e-06	8.38e-06	CbGpPWpGaD
Bosutinib—IRAK4—Immune System—IL6—osteoporosis	3.97e-06	8.38e-06	CbGpPWpGaD
Bosutinib—FYN—Developmental Biology—IL6—osteoporosis	3.96e-06	8.37e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CA2—osteoporosis	3.96e-06	8.37e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—OXCT1—osteoporosis	3.96e-06	8.37e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IL6R—osteoporosis	3.95e-06	8.35e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Developmental Biology—IL6—osteoporosis	3.94e-06	8.32e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—POMC—osteoporosis	3.92e-06	8.28e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—IRS1—osteoporosis	3.89e-06	8.21e-06	CbGpPWpGaD
Bosutinib—ERBB3—Disease—MYC—osteoporosis	3.89e-06	8.2e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—KL—osteoporosis	3.88e-06	8.19e-06	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—TGFB1—osteoporosis	3.88e-06	8.19e-06	CbGpPWpGaD
Bosutinib—ERBB3—Disease—TGFB1—osteoporosis	3.88e-06	8.18e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—MGLL—osteoporosis	3.86e-06	8.15e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IRS2—osteoporosis	3.84e-06	8.1e-06	CbGpPWpGaD
Bosutinib—CSNK1E—Disease—IL6—osteoporosis	3.83e-06	8.09e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—IRS1—osteoporosis	3.83e-06	8.09e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—IL6R—osteoporosis	3.82e-06	8.07e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—IL6R—osteoporosis	3.81e-06	8.05e-06	CbGpPWpGaD
Bosutinib—HCK—Immune System—IL6—osteoporosis	3.81e-06	8.04e-06	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—TGFB1—osteoporosis	3.8e-06	8.03e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—IRS2—osteoporosis	3.8e-06	8.02e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—IGF1—osteoporosis	3.77e-06	7.96e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—LEP—osteoporosis	3.75e-06	7.93e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—IRS1—osteoporosis	3.74e-06	7.91e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IRS2—osteoporosis	3.74e-06	7.9e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling by GPCR—IL6—osteoporosis	3.73e-06	7.87e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Innate Immune System—IL6—osteoporosis	3.72e-06	7.86e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—IL1B—osteoporosis	3.7e-06	7.82e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—POMC—osteoporosis	3.69e-06	7.79e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IRS2—osteoporosis	3.66e-06	7.74e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—LEP—osteoporosis	3.66e-06	7.73e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—IL6R—osteoporosis	3.65e-06	7.71e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Innate Immune System—IL6—osteoporosis	3.63e-06	7.67e-06	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—TNF—osteoporosis	3.62e-06	7.64e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—IL1B—osteoporosis	3.61e-06	7.63e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IRS2—osteoporosis	3.61e-06	7.62e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—IL6R—osteoporosis	3.6e-06	7.6e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—IRS1—osteoporosis	3.59e-06	7.58e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IRS2—osteoporosis	3.59e-06	7.58e-06	CbGpPWpGaD
Bosutinib—ERBB4—Immune System—IL6—osteoporosis	3.59e-06	7.58e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—LEP—osteoporosis	3.59e-06	7.57e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—ESR1—osteoporosis	3.58e-06	7.57e-06	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—MYC—osteoporosis	3.57e-06	7.54e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—ADCY5—osteoporosis	3.56e-06	7.52e-06	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—TGFB1—osteoporosis	3.56e-06	7.52e-06	CbGpPWpGaD
Bosutinib—LYN—Innate Immune System—IL6—osteoporosis	3.56e-06	7.51e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—IGF1—osteoporosis	3.55e-06	7.49e-06	CbGpPWpGaD
Bosutinib—ABL1—Innate Immune System—IL6—osteoporosis	3.54e-06	7.47e-06	CbGpPWpGaD
Bosutinib—PTK2B—Immune System—IL6—osteoporosis	3.54e-06	7.47e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—IL1B—osteoporosis	3.54e-06	7.47e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—LEP—osteoporosis	3.53e-06	7.46e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—IL1B—osteoporosis	3.52e-06	7.43e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—IL6R—osteoporosis	3.52e-06	7.43e-06	CbGpPWpGaD
Bosutinib—HCK—Disease—IL6—osteoporosis	3.52e-06	7.43e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—LEP—osteoporosis	3.51e-06	7.42e-06	CbGpPWpGaD
Bosutinib—FYN—Innate Immune System—IL6—osteoporosis	3.5e-06	7.39e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—ESR1—osteoporosis	3.5e-06	7.38e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—IL1B—osteoporosis	3.48e-06	7.35e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Innate Immune System—IL6—osteoporosis	3.48e-06	7.35e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—IL1B—osteoporosis	3.46e-06	7.31e-06	CbGpPWpGaD
Bosutinib—BLK—Immune System—IL6—osteoporosis	3.45e-06	7.29e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—SPP1—osteoporosis	3.45e-06	7.28e-06	CbGpPWpGaD
Bosutinib—FGR—Immune System—IL6—osteoporosis	3.44e-06	7.26e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—ADCY5—osteoporosis	3.43e-06	7.25e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—ESR1—osteoporosis	3.42e-06	7.23e-06	CbGpPWpGaD
Bosutinib—EGFR—Developmental Biology—IL6—osteoporosis	3.42e-06	7.23e-06	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—IL6—osteoporosis	3.39e-06	7.15e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—IL6R—osteoporosis	3.37e-06	7.12e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—ESR1—osteoporosis	3.37e-06	7.12e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—ESR1—osteoporosis	3.35e-06	7.08e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IRS1—osteoporosis	3.35e-06	7.07e-06	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—IL6—osteoporosis	3.32e-06	7.02e-06	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—IL6—osteoporosis	3.32e-06	7.02e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—SPP1—osteoporosis	3.32e-06	7.01e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—IRS1—osteoporosis	3.32e-06	7e-06	CbGpPWpGaD
Bosutinib—ERBB4—Disease—IL6—osteoporosis	3.31e-06	7e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—ENO1—osteoporosis	3.29e-06	6.95e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—IDH2—osteoporosis	3.28e-06	6.93e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IRS1—osteoporosis	3.27e-06	6.9e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PSMA2—osteoporosis	3.24e-06	6.85e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PSMA5—osteoporosis	3.24e-06	6.85e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—POMC—osteoporosis	3.22e-06	6.81e-06	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—IL6—osteoporosis	3.21e-06	6.78e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IRS1—osteoporosis	3.2e-06	6.76e-06	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—IL6—osteoporosis	3.16e-06	6.68e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IRS1—osteoporosis	3.15e-06	6.65e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—POMC—osteoporosis	3.15e-06	6.64e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IL6R—osteoporosis	3.15e-06	6.64e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IRS1—osteoporosis	3.13e-06	6.62e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IRS2—osteoporosis	3.12e-06	6.58e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—IL6R—osteoporosis	3.11e-06	6.58e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IGF1—osteoporosis	3.1e-06	6.55e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CYP27A1—osteoporosis	3.09e-06	6.52e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—MYC—osteoporosis	3.09e-06	6.52e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—POMC—osteoporosis	3.08e-06	6.51e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—TGFB1—osteoporosis	3.08e-06	6.5e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IL6R—osteoporosis	3.07e-06	6.48e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—LEP—osteoporosis	3.05e-06	6.44e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—MYC—osteoporosis	3.04e-06	6.42e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—ADCY5—osteoporosis	3.04e-06	6.42e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—TGFB1—osteoporosis	3.03e-06	6.41e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—POMC—osteoporosis	3.03e-06	6.4e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IGF1—osteoporosis	3.03e-06	6.39e-06	CbGpPWpGaD
Bosutinib—EGFR—Innate Immune System—IL6—osteoporosis	3.02e-06	6.39e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—POMC—osteoporosis	3.02e-06	6.37e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IL1B—osteoporosis	3.01e-06	6.35e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IL6R—osteoporosis	3.01e-06	6.35e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IRS2—osteoporosis	3e-06	6.34e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ACP5—osteoporosis	3e-06	6.34e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IGF1—osteoporosis	2.96e-06	6.26e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IL6R—osteoporosis	2.96e-06	6.25e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IL6R—osteoporosis	2.94e-06	6.21e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—SPP1—osteoporosis	2.94e-06	6.21e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—LEP—osteoporosis	2.94e-06	6.21e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—MYC—osteoporosis	2.93e-06	6.19e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—TGFB1—osteoporosis	2.92e-06	6.17e-06	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—IL6—osteoporosis	2.92e-06	6.17e-06	CbGpPWpGaD
Bosutinib—ERBB3—Disease—IL6—osteoporosis	2.92e-06	6.17e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IGF1—osteoporosis	2.92e-06	6.16e-06	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—IL6—osteoporosis	2.91e-06	6.15e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—ESR1—osteoporosis	2.91e-06	6.15e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IGF1—osteoporosis	2.9e-06	6.13e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—IL1B—osteoporosis	2.9e-06	6.12e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—MYC—osteoporosis	2.82e-06	5.96e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—MYC—osteoporosis	2.82e-06	5.96e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—TGFB1—osteoporosis	2.82e-06	5.95e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—TGFB1—osteoporosis	2.82e-06	5.95e-06	CbGpPWpGaD
Bosutinib—PTK2—Immune System—IL6—osteoporosis	2.82e-06	5.95e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—ESR1—osteoporosis	2.81e-06	5.93e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—TPI1—osteoporosis	2.79e-06	5.89e-06	CbGpPWpGaD
Bosutinib—YES1—Immune System—IL6—osteoporosis	2.78e-06	5.86e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IRS1—osteoporosis	2.72e-06	5.75e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—MYC—osteoporosis	2.72e-06	5.75e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—TGFB1—osteoporosis	2.71e-06	5.73e-06	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—IL6—osteoporosis	2.68e-06	5.67e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—MYC—osteoporosis	2.66e-06	5.62e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IRS2—osteoporosis	2.66e-06	5.62e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—TGFB1—osteoporosis	2.66e-06	5.61e-06	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—IL6—osteoporosis	2.63e-06	5.56e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—CYP19A1—osteoporosis	2.63e-06	5.56e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—P4HB—osteoporosis	2.62e-06	5.54e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IRS1—osteoporosis	2.62e-06	5.54e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—POMC—osteoporosis	2.62e-06	5.53e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—LEP—osteoporosis	2.6e-06	5.5e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—MYC—osteoporosis	2.6e-06	5.49e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—TGFB1—osteoporosis	2.59e-06	5.47e-06	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—IL6—osteoporosis	2.58e-06	5.45e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GAPDH—osteoporosis	2.58e-06	5.44e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—IL1B—osteoporosis	2.57e-06	5.42e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IL6R—osteoporosis	2.56e-06	5.4e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—POMC—osteoporosis	2.53e-06	5.33e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IGF1—osteoporosis	2.52e-06	5.32e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—RAP1A—osteoporosis	2.51e-06	5.3e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—MYC—osteoporosis	2.5e-06	5.29e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—TGFB1—osteoporosis	2.5e-06	5.27e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—MYC—osteoporosis	2.49e-06	5.26e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—ESR1—osteoporosis	2.48e-06	5.25e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—TGFB1—osteoporosis	2.48e-06	5.25e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—IL6—osteoporosis	2.48e-06	5.24e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL6R—osteoporosis	2.46e-06	5.2e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IGF1—osteoporosis	2.43e-06	5.13e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—MYC—osteoporosis	2.42e-06	5.11e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—TGFB1—osteoporosis	2.42e-06	5.1e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—MYC—osteoporosis	2.39e-06	5.04e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TGFB1—osteoporosis	2.38e-06	5.03e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—IL6—osteoporosis	2.37e-06	5.01e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IRS1—osteoporosis	2.32e-06	4.9e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—IL6—osteoporosis	2.32e-06	4.9e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—IL6—osteoporosis	2.29e-06	4.83e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—MYC—osteoporosis	2.27e-06	4.78e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TGFB1—osteoporosis	2.26e-06	4.77e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—POMC—osteoporosis	2.24e-06	4.72e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—IL6—osteoporosis	2.22e-06	4.69e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—IL6—osteoporosis	2.2e-06	4.65e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL6R—osteoporosis	2.18e-06	4.6e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—IL6—osteoporosis	2.17e-06	4.58e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—MYC—osteoporosis	2.16e-06	4.57e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—TGFB1—osteoporosis	2.16e-06	4.56e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—ADCY5—osteoporosis	2.15e-06	4.54e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IGF1—osteoporosis	2.15e-06	4.54e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—GPX1—osteoporosis	2.14e-06	4.53e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—MYC—osteoporosis	2.13e-06	4.5e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TGFB1—osteoporosis	2.13e-06	4.49e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—IL6—osteoporosis	2.12e-06	4.48e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—IL6—osteoporosis	2.12e-06	4.48e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—IL6—osteoporosis	2.11e-06	4.47e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—MYC—osteoporosis	2.08e-06	4.4e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—TGFB1—osteoporosis	2.08e-06	4.39e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—IL6—osteoporosis	2.07e-06	4.37e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—IL6—osteoporosis	2.06e-06	4.35e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—IL6—osteoporosis	2.05e-06	4.32e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—IL6—osteoporosis	2.04e-06	4.3e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ENO1—osteoporosis	2.03e-06	4.28e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—IL6—osteoporosis	2.03e-06	4.28e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—IL6—osteoporosis	2e-06	4.23e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PSMA2—osteoporosis	2e-06	4.22e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PSMA5—osteoporosis	2e-06	4.22e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—MTHFR—osteoporosis	1.98e-06	4.18e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—IL6—osteoporosis	1.95e-06	4.12e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—IL6—osteoporosis	1.93e-06	4.07e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—IL6—osteoporosis	1.88e-06	3.97e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—IL6—osteoporosis	1.87e-06	3.95e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MYC—osteoporosis	1.86e-06	3.94e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TGFB1—osteoporosis	1.86e-06	3.93e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—MYC—osteoporosis	1.85e-06	3.9e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—TGFB1—osteoporosis	1.84e-06	3.89e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—IL6—osteoporosis	1.82e-06	3.84e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MYC—osteoporosis	1.82e-06	3.84e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TGFB1—osteoporosis	1.81e-06	3.83e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—IL6—osteoporosis	1.8e-06	3.79e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MYC—osteoporosis	1.78e-06	3.76e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TGFB1—osteoporosis	1.78e-06	3.75e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IL6—osteoporosis	1.76e-06	3.72e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MYC—osteoporosis	1.75e-06	3.7e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TGFB1—osteoporosis	1.75e-06	3.69e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MYC—osteoporosis	1.74e-06	3.68e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TGFB1—osteoporosis	1.74e-06	3.67e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—IL6—osteoporosis	1.7e-06	3.6e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—IL6—osteoporosis	1.7e-06	3.58e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—IL6—osteoporosis	1.63e-06	3.43e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CYP19A1—osteoporosis	1.62e-06	3.42e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—IL6—osteoporosis	1.6e-06	3.39e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—POMC—osteoporosis	1.58e-06	3.34e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—IL6—osteoporosis	1.57e-06	3.31e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MYC—osteoporosis	1.51e-06	3.2e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TGFB1—osteoporosis	1.51e-06	3.19e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—IL6—osteoporosis	1.5e-06	3.17e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MYC—osteoporosis	1.46e-06	3.08e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TGFB1—osteoporosis	1.46e-06	3.07e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IL6—osteoporosis	1.4e-06	2.96e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—IL6—osteoporosis	1.39e-06	2.93e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IL6—osteoporosis	1.37e-06	2.89e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IL6—osteoporosis	1.34e-06	2.83e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ADCY5—osteoporosis	1.32e-06	2.8e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GPX1—osteoporosis	1.32e-06	2.79e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IL6—osteoporosis	1.32e-06	2.78e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IL6—osteoporosis	1.31e-06	2.77e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MYC—osteoporosis	1.29e-06	2.73e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TGFB1—osteoporosis	1.29e-06	2.72e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—MTHFR—osteoporosis	1.22e-06	2.57e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IL6—osteoporosis	1.14e-06	2.4e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL6—osteoporosis	1.1e-06	2.32e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—POMC—osteoporosis	9.75e-07	2.06e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL6—osteoporosis	9.71e-07	2.05e-06	CbGpPWpGaD
